In Parliament

The Department has undertaken sensitivity testing of the Innova SARS-CoV-2 Antigen Rapid Qualitative Test when the test is used according to

T-cell tests are utilised in specific groups for clinical or research purposes including the Protective Immunity from T-Cells in Healthcare

No assessment has been made on the feasibility and efficacy of providing monthly COVID-19 antibody tests to care homes.

No specific assessment has been made.

The Government does not endorse, recommend, or approve any private test providers and the Department has not issued private companies with s

Due to commercial sensitivities, the Department does not publish the specific reasons for organisations being removed from the GOV.UK listin

Public Health England has not made an estimate of when herd immunity to COVID-19 will be reached in the United Kingdom.

Patients have the ability to opt-out of the new General Practice Data for Planning and Research (GPDPR) programme and the dataset will alway

Since requirements were introduced for international travel testing, the costs of travel testing have fallen significantly.

From 16 August 2021, those who are fully vaccinated, participants of approved vaccine trials, individuals under 18 years and 6 months of age